Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14441948 | 0.96 | HDAC3 (0.44) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24437376 | 0.88 | HPSE (0.38) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14181034 | 0.87 | HDAC3 (0.51) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL24437330 | 0.85 | SIRT2 (0.42) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL889828 | 0.85 | HDAC3 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL13160540 | 0.84 | HDAC3 (0.48) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL14441842 | 0.81 | HDAC3 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL6777572 | 0.80 | SIRT2 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4400235 | 0.80 | EPHX2 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2392134 | 0.76 | HDAC3 (0.39) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454526-B2 | Method for producing pyrrole-imidazole (poly)amide | KANEKA CORPORATION (JP) | 2025-10-28 | — | — | US | disclosed |
| CN-115362144-A | Process for producing amide bond-containing compound | 株式会社钟化 | 2022-11-18 | — | — | CN | disclosed |
| US-20220153727-A1 | METHOD FOR PRODUCING PYRROLE-IMIDAZOLE (POLY)AMIDE | KANEKA CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-20220153727-A1 | METHOD FOR PRODUCING PYRROLE-IMIDAZOLE (POLY)AMIDE | KANEKA CORPORATION (JP) | 2022-05-19 | — | — | US | disclosed |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-22 | — | — | US | disclosed |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-22 | — | — | US | disclosed |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | BRISTOL-MYERS SQUIBB COMPANY | 2018-04-26 | — | — | US | disclosed |
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| US-6303312-B1 | MODIFYING CELL PHENOTYPE; MEDICAL RESEARCH AND THERAPY | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2001-10-16 | — | — | US | disclosed |
| US-6143901-A | FORMINGA SPECIFIC COMPLEX BETWEEN A TARGET SEQUENCE OF DOUBLE STRANDED DNA AND AN OLIGOMER OR POLYMER OF N-METHYLPYRROLE CARBOXAMIDE AND N-METHYLIMIDAZOLE CARBOXAMID WHEREIN N-HETEROCYLCES ARE CONNCETED WITH AN AMINO ACID LINKING GROUP | GENESOFT, INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6090947-A | Method for the synthesis of pyrrole and imidazole carboxamides on a solid support | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-07-18 | — | — | US | disclosed |
| US-6084102-A | THE OLIGONUCLEOTIDE IS COMPLEMENTARY TO A TARGET SEQUENCE OF SINGLE STRANDED OR DOUBLE STRANDED DNA, RNA OR HYBRIDS AND, WHEN USED AS A PROBE, BINDS MORE STRONGLY BECAUSE OF THE BOUND MINOR GROVE BINDER; MEDICAL DIAGNOSIS; ANTISENSE THERAPY | EPOCH PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| EP-0986539-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5998140-A | COMPLEXES OF CELL WITH OLIGOMER | THE SCRIPPS RESEARCH INSTITUTE (US) | 1999-12-07 | — | — | US | disclosed |
| WO-1998049142-A1 | DNA-BINDING PYRROLE AND IMIDAZOLE POLYAMIDE DERIVATIVES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-05 | — | — | WO | disclosed |
| US-5801155-A | Covalently linked oligonucleotide minor grove binder conjugates | EPOCH PHARMACEUTICALS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0819133-A2 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | EPOCH PHARMACEUTICALS, INC. (US) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996032496-A2 | COVALENTLY LINKED OLIGONUCLEOTIDE MINOR GROOVE BINDER CONJUGATES | MICROPROBE CORPORATION (US) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153727-A1 | METHOD FOR PRODUCING PYRROLE-IMIDAZOLE (POLY)AMIDE | DDC, PAM, AADAC | HDAC3 594/4885HDAC4 724/4885HDAC1 686/4885 |
| US-20180110873-A1 | ANTIPROLIFERATIVE COMPOUNDS AND CONJUGATES MADE THEREFROM | MKI67, HDGF, PCLAF | HDAC3 2960/4885HDAC4 1358/4885HDAC1 556/4885 |
| US-10869934-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | HDAC3 2960/4885HDAC4 1358/4885HDAC1 556/4885 |
| US-10398783-B2 | Antiproliferative compounds and conjugates made therefrom | MKI67, HDGF, PCLAF | HDAC3 2960/4885HDAC4 1358/4885HDAC1 556/4885 |
| US-12454526-B2 | Method for producing pyrrole-imidazole (poly)amide | DDC, PAM, AADAC | HDAC3 594/4885HDAC4 724/4885HDAC1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.